Seth J. Orlow
Director/Board Member at ALMIRALL, S.A.
Profile
Seth J.
Orlow was the founder of Ivrea Pharmaceuticals, Inc. founded in 2005 where he held the title of Director.
Dr. Orlow is also the founder of Anaderm Research Corp.
Currently, Dr. Orlow holds the title of Professor & Chairman-Perelman Dermatology at NYU Grossman School of Medicine since 2006, Independent Director at Almirall SA since 2016, and Director at R2 Dermatology, Inc., R2 Technologies, Inc. (California), and New York University.
Dr. Orlow's former positions include Director at Coapt Systems, Inc., Protez Pharmaceuticals, Inc., and Transave, Inc., Managing Director at Easton Capital Investment Group, and Trustee at Dermatology Foundation.
Dr. Orlow holds a doctorate degree from Albert Einstein College of Medicine, Inc. and an undergraduate degree from Harvard College.
Seth J. Orlow active positions
| Companies | Position | Start |
|---|---|---|
| ALMIRALL, S.A. | Director/Board Member | 2015-12-31 |
| New York University | Corporate Officer/Principal | - |
| R2 Dermatology, Inc. | Director/Board Member | - |
R2 Technologies, Inc. (California)
 R2 Technologies, Inc. (California) Medical SpecialtiesHealth Technology R2 Technologies, Inc. is an American California-based company founded in 2014 by Irina Erenburg. The company specializes in developing groundbreaking technology that fights inflammation and provides precision cold treatment for the face and skin. The company's technology has been proven effective and is available for use in medical practices. The CEO is Tim Holt. | Director/Board Member | - |
| Nyu Grossman School of Medicine | Corporate Officer/Principal | 2005-12-31 |
Former positions of Seth J. Orlow
| Companies | Position | End |
|---|---|---|
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Director/Board Member | - |
| Dermatology Foundation | Director/Board Member | - |
| Anaderm Research Corp. | Founder | - |
Ivrea Pharmaceuticals, Inc.
 Ivrea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ivrea Pharmaceuticals, Inc. develops pharmaceuticals for dermatologic conditions. The company's clinical trials include IVR 101/102 and IVR 103. Ivrea Pharmaceuticals was founded by Maurizio V. Cattaneo in May 2005 and is headquartered in Quincy, MA. | Founder | - |
| ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Seth J. Orlow
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALMIRALL, S.A. | Health Technology |
| Private companies | 9 |
|---|---|
Coapt Systems, Inc.
 Coapt Systems, Inc. BiotechnologyHealth Technology Coapt Systems, Inc. designs, develops, manufactures and markets bio absorbable implants for surgeons to use in plastic surgery to fixate soft tissue to other soft tissue and bone. The company was founded in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Ivrea Pharmaceuticals, Inc.
Ivrea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ivrea Pharmaceuticals, Inc. develops pharmaceuticals for dermatologic conditions. The company's clinical trials include IVR 101/102 and IVR 103. Ivrea Pharmaceuticals was founded by Maurizio V. Cattaneo in May 2005 and is headquartered in Quincy, MA. | Health Technology |
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Easton Capital Investment Group
 Easton Capital Investment Group Investment ManagersFinance Easton Capital Investment Group (Easton) is a Venture Capital firm which is founded in 2000 by John H. Friedman. The firm is headquartered in New York ,US. | Finance |
| Dermatology Foundation | |
| Anaderm Research Corp. | |
| R2 Dermatology, Inc. | |
R2 Technologies, Inc. (California)
R2 Technologies, Inc. (California) Medical SpecialtiesHealth Technology R2 Technologies, Inc. is an American California-based company founded in 2014 by Irina Erenburg. The company specializes in developing groundbreaking technology that fights inflammation and provides precision cold treatment for the face and skin. The company's technology has been proven effective and is available for use in medical practices. The CEO is Tim Holt. | Health Technology |
- Stock Market
- Insiders
- Seth J. Orlow
